

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

	Three Months Ended March 31, 2011	
	International Net Sales	Total Net Sales
Net sales, as reported	\$ 57,444	\$ 135,386
Currency impact as compared to prior period	(1,742)	(1,742)
Net sales, excluding the impact of foreign currency	\$ 55,702	\$ 133,644

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2011	March 31, 2010
<b>Operating Income</b>		
<b>Operating income, as reported</b>	\$ 11,896	\$ 3,637
<i>Reconciling items impacting Gross Profit:</i>		
Non-cash, stock-based compensation	347	340
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>		
Non-cash, stock-based compensation	2,068	2,267
U.S. governmental inquiries/DPA related	2,182	8,071
Total	4,250	10,338
<i>Reconciling items impacting Research and Development expenses:</i>		
Non-cash, stock-based compensation	445	398
<i>Other Reconciling Items:</i>		
Restructuring charges	-	544
<b>Operating income, as adjusted</b>	\$ 16,938	\$ 15,257
<b>Operating income, as adjusted, as a percentage of net sales</b>	12.5%	11.6%

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
**(continued)**

	<u>Three Months Ended</u>	
	<u>March 31,</u> <u>2011</u>	<u>March 31,</u> <u>2010</u>
<b>Net Income</b>		
<b>Income before income taxes, as reported</b>	\$ 5,602	\$ 1,997
U.S. governmental inquiries/DPA related	2,182	8,071
Non-cash, stock-based compensation	2,860	3,005
Restructuring charges	-	544
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	4,099	-
<b>Income before income taxes, as adjusted</b>	<u>14,743</u>	<u>13,617</u>
<b>Provision for income taxes, as reported</b>	2,010	2,522
U.S. governmental inquiries/DPA related	852	1,580
Non-cash, stock-based compensation	847	836
Restructuring charges	-	211
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	1,599	-
<b>Provision for income taxes, as adjusted</b>	<u>5,308</u>	<u>5,149</u>
<b>Effective tax rate, as adjusted</b>	<u>36.0%</u>	<u>37.8%</u>
<b>Net income, as adjusted</b>	<u>\$ 9,435</u>	<u>\$ 8,468</u>

	<u>Three Months Ended</u> <u>March 31, 2011</u>		<u>Three Months Ended</u> <u>March 31, 2010</u>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
<b>Basic net income (loss)</b>	\$ 3,592	\$ 9,435	\$ (525)	\$ 8,468
Interest expense on convertible notes	N/A	787	N/A	935
<b>Diluted net income (loss)</b>	\$ 3,592	\$ 10,222	\$ (525)	\$ 9,403
<b>Basic shares</b>	38,033	38,033	37,540	37,540
Dilutive effect of stock options and restricted shares	294	294	N/A	283
Dilutive effect of convertible notes	N/A	4,962	N/A	6,126
<b>Diluted shares</b>	38,327	43,289	37,540	43,949
<b>Net income (loss) per share, diluted</b>	<u>\$ 0.09</u>	<u>\$ 0.24</u>	<u>\$ (0.01)</u>	<u>\$ 0.21</u>

	<u>Three Months Ended</u>	
	<u>March 31,</u> <u>2011</u>	<u>March 31,</u> <u>2010</u>
<b>Net Income per Diluted Share</b>		
<b>Net income (loss), as reported, per diluted share</b>	\$ 0.09	\$ (0.01)
Interest expense on convertible notes	0.02	0.02
Dilutive effect of convertible notes	(0.01)	0.00
U.S. governmental inquiries/DPA related	0.03	0.15
Non-cash, stock-based compensation	0.05	0.05
Restructuring charges	-	0.01
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	0.06	-
<b>Net income, as adjusted, per diluted share</b>	<u>\$ 0.24</u>	<u>\$ 0.21</u>